Eilertsen Karl-Erik, Østerud Bjarne
Department of Biochemistry, Institute of Medical Biology, Faculty of Medicine, University of Tromsø, Norway.
Blood Coagul Fibrinolysis. 2004 Oct;15(7):521-38. doi: 10.1097/00001721-200410000-00001.
The transmembrane glycoprotein tissue factor (TF) is the initiator of the coagulation cascade in vivo. When TF is exposed to blood, it forms a high-affinity complex with the coagulation factors factor VII/activated factor VIIa (FVII/VIIa), activating factor IX and factor X, and ultimately leading to the formation of an insoluble fibrin clot. TF plays an essential role in hemostasis by restraining hemorrhage after vessel wall injury. An overview of biological and physiological aspects of TF, covering aspects consequential for thrombosis and hemostasis such as TF cell biology and biochemistry, blood-borne (circulating) TF, TF associated with microparticles, TF encryption-decryption, and regulation of TF activity and expression is presented. However, the emerging role of TF in the pathogenesis of diseases such as sepsis, atherosclerosis, certain cancers and diseases characterized by pathological fibrin deposition such as disseminated intravascular coagulation and thrombosis, has directed attention to the development of novel inhibitors of tissue factor for use as antithrombotic drugs. The main advantage of inhibitors of the TF*FVIIa pathway is that such inhibitors have the potential of inhibiting the coagulation cascade at its earliest stage. Thus, such therapeutics exert minimal disturbance of systemic hemostasis since they act locally at the site of vascular injury.
跨膜糖蛋白组织因子(TF)是体内凝血级联反应的启动因子。当TF暴露于血液中时,它会与凝血因子VII/活化凝血因子VIIa(FVII/VIIa)形成高亲和力复合物,激活因子IX和因子X,最终导致不溶性纤维蛋白凝块的形成。TF通过限制血管壁损伤后的出血在止血过程中发挥重要作用。本文概述了TF的生物学和生理学方面,涵盖了与血栓形成和止血相关的方面,如TF细胞生物学和生物化学、血源性(循环)TF、与微粒相关的TF、TF加密-解密以及TF活性和表达的调节。然而,TF在脓毒症、动脉粥样硬化、某些癌症以及以病理性纤维蛋白沉积为特征的疾病(如弥散性血管内凝血和血栓形成)的发病机制中所起的新作用,已将注意力转向开发新型组织因子抑制剂用作抗血栓药物。TF*FVIIa途径抑制剂的主要优点是,此类抑制剂有可能在凝血级联反应的最早阶段对其进行抑制。因此,此类治疗方法对全身止血的干扰最小,因为它们在血管损伤部位局部起作用。